doi: 10.1161/01.ATV.0000133317.49796.0E
© 2004 American Heart Association, Inc.
NCEP Report |
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Abstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Key Words: cholesterol • trials • lipoproteins • coronary disease
This article has been cited by other articles:
 |
|
 |
|
  J. M.S. Lee, M. D. Robson, L.-M. Yu, C. C. Shirodaria, C. Cunnington, I. Kylintireas, J. E. Digby, T. Bannister, A. Handa, F. Wiesmann, et al. Effects of high-dose modified-release nicotinic Acid on atherosclerosis and vascular function a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol., November 3, 2009; 54(19): 1787 - 1794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Cooney, A. L. Dudina, and I. M. Graham Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1209 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J Key, P. N Appleby, E. A Spencer, R. C Travis, A. W Roddam, and N. E Allen Mortality in British vegetarians: results from the European Prospective Investigation into Cancer and Nutrition (EPIC-Oxford) Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1613S - 1619S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Briel, I. Ferreira-Gonzalez, J. J You, P. J Karanicolas, E. A Akl, P. Wu, B. Blechacz, D. Bassler, X. Wei, A. Sharman, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ, February 16, 2009; 338(feb16_1): b92 - b92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Davidson Is LDL-C Passed Its Prime?: The Emerging Role of Non-HDL, LDL-P, and ApoB in CHD Risk Assessment Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1582 - 1583. [Full Text] [PDF]
|
|
|
|
 |
|
 P Hadji Menopausal symptoms and adjuvant therapy-associated adverse events Endocr. Relat. Cancer, March 1, 2008; 15(1): 73 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lu, W. Jiang, J.-H. Yang, P.-Y. Chang, J. P. Walterscheid, H.-H. Chen, M. Marcelli, D. Tang, Y.-T. Lee, W. S.L. Liao, et al. Electronegative LDL Impairs Vascular Endothelial Cell Integrity in Diabetes by Disrupting Fibroblast Growth Factor 2 (FGF2) Autoregulation Diabetes, January 1, 2008; 57(1): 158 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mancia, F. Messerli, G. Bakris, Q. Zhou, A. Champion, and C. J. Pepine Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study Hypertension, August 1, 2007; 50(2): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugita, H. Sugita, and M. Kaneki Farnesyltransferase Inhibitor, Manumycin A, Prevents Atherosclerosis Development and Reduces Oxidative Stress in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1390 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M S Lee and R. P Choudhury Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart, May 1, 2007; 93(5): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P Padala, P. R Padala, and J. F Potter Simvastatin-Induced Decline in Cognition Ann. Pharmacother., October 1, 2006; 40(10): 1880 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Briel, G. G. Schwartz, P. L. Thompson, J. A. de Lemos, M. A. Blazing, G.-A. van Es, M. Kayikcioglu, H.-R. Arntz, F. R. den Hartog, N. J. G. M. Veeger, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA, May 3, 2006; 295(17): 2046 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Hirsch, Z. J. Haskal, N. R. Hertzer, C. W. Bakal, M. A. Creager, J. L. Halperin, L. F. Hiratzka, W. R.C. Murphy, J. W. Olin, J. B. Puschett, et al. ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1239 - 1312. [Full Text] [PDF]
|
|
|
|
 |
|
 L.-P. Duan, H. H. Wang, A. Ohashi, and D. Q.-H. Wang Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects Am J Physiol Gastrointest Liver Physiol, February 1, 2006; 290(2): G269 - G276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Forrester, R. Makkar, and P.K. Shah Increasing High-Density Lipoprotein Cholesterol in Dyslipidemia by Cholesteryl Ester Transfer Protein Inhibition: An Update for Clinicians Circulation, April 12, 2005; 111(14): 1847 - 1854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Studer, M. Briel, B. Leimenstoll, T. R. Glass, and H. C. Bucher Effect of Different Antilipidemic Agents and Diets on Mortality: A Systematic Review Arch Intern Med, April 11, 2005; 165(7): 725 - 730. [Abstract] [Full Text] [PDF]
|
|